date,title,source
Oct-22-18,Mirati Shares Fall After Cancer Trial Progress Report,TheStreet.com
Oct-22-18,Why Mirati Therapeutics Inc. Is Plunging Today,Motley Fool
Oct-22-18,Mirati Therapeutics stock drops 19.5% after cancer trial results,MarketWatch
Oct-22-18,Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial,PR Newswire
Oct-25-18,"Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook  Fundamental Analysis, Calculating Forward Movement",GlobeNewswire
Oct-30-18,"Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer",PR Newswire
Nov-05-18,Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting,PR Newswire
Nov-06-18,Mirati: 3Q Earnings Snapshot,Associated Press
Nov-06-18,Mirati Therapeutics Reports Third Quarter Financial Results,PR Newswire
Nov-07-18,Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference,PR Newswire
Nov-08-18,Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors,PR Newswire
Nov-08-18,Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors,PR Newswire
Nov-09-18,Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting,PR Newswire
Nov-09-18,Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting,PR Newswire
